Evidence map›Paper›PMID 40328917›Full record

ArticleBritish journal of cancer2025

Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.

Thomas F Stoop, Y H Andrew Wu, Atsushi Oba, Mahsoem Ali, Isabel M Feld, Mohammed H Al-Musawi, Ajay Jain, Akio Saiura, Alain Sauvanet, Alessandro Coppola and 46 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Ellagic Acid Enhances RSL3-Induced Ferroptosis by Inhibiting the Nrf2/HO-1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

56 authors.

Thomas F Stoop *Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. t.f.stoop@amsterdamUMC.nl.ORCID http://orcid.org/0000-0003-3328-4516
Y H Andrew Wu *Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Atsushi Oba *Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-7315-0830
Mahsoem AliCancer Center Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0511-6323
Isabel M FeldAmsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands.
Mohammed H Al-MusawiClinical Trials of Office, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Ajay JainDivision of Surgical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Akio SaiuraDepartment of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Alain SauvanetDepartment of HPB Surgery and Liver Transplantation, Hôpital Beaujon, University Paris Cité, INSERM Unité Mixte de Recherche 1149, Clichy, France.
Alessandro CoppolaDipartimento di Chirurgia Sapienza Università di Roma, Rome, Italy.
Ammar A JavedAmsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Braden N MillerDivision of Surgical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Daisuke HashimotoDepartment of Surgery, Kansai Medical University, Osaka, Japan.
Damiano CaputoFondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Dyre KleiveDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Elisabetta SereniDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Geert KazemierCancer Center Amsterdam, Amsterdam, The Netherlands.
Giulio BelfioriPancreatic Surgery, IRCCS San Raffaele Hospital, Vita-Salute University, Milano, Italy.
Hirofumi IshidaDepartment of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Jacob L van DamDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-6947-9035
Jeanne DembinskiDepartment of HPB Surgery and Liver Transplantation, Hôpital Beaujon, University Paris Cité, INSERM Unité Mixte de Recherche 1149, Clichy, France.
Keiichi AkahoshiDepartment of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Keith J RobertsHepato-Pancreato-Biliary Unit, Department of Surgery, University Hospitals of Birmingham, Birmingham, UK.
Kimitaka TanakaDepartment of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Hokkaido, Japan.
Knut J LaboriDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Massimo FalconiPancreatic Surgery, IRCCS San Raffaele Hospital, Vita-Salute University, Milano, Italy.
Michael G HouseDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Motokazu SugimotoDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Minoru TanabeDepartment of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Naoto GotohdaDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Nikolaos ChatzizachariasHepato-Pancreato-Biliary Unit, Department of Surgery, University Hospitals of Birmingham, Birmingham, UK.
Paul S KrohnDepartment of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Safi DokmakDepartment of HPB Surgery and Liver Transplantation, Hôpital Beaujon, University Paris Cité, INSERM Unité Mixte de Recherche 1149, Clichy, France.
Salvador Rodriguez FrancoDivision of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Satoshi HiranoDepartment of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Hokkaido, Japan.
Stefan K BurgdorfDepartment of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Stefano CrippaPancreatic Surgery, IRCCS San Raffaele Hospital, Vita-Salute University, Milano, Italy.
Sohei SatoiDivision of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Trang K NguyenDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Tomohisa YamamotoDepartment of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Hokkaido, Japan.
Toru NakamuraDepartment of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Hokkaido, Japan.ORCID http://orcid.org/0000-0003-3999-9627
Yuta UshidaDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan.
Vismaya BachuDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William R BurnsDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yosuke InoueDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan.
Yu TakahashiDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3066-023X
Zohra AslamiDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard D SchulickDivision of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Jin HeDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9149-2247
Wells MessersmithDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Marc G BesselinkAmsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands.
Richard A BurkhartDivision of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johanna W WilminkCancer Center Amsterdam, Amsterdam, The Netherlands.
Marco Del ChiaroDivision of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
International Consortium on Pancreatic Cancer Surgery and Oncology (ICON)

Funding

CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Elizabeth Selvin · 1985 to 2026
$17.5M
NHLBI NIH HHS T32 HL007024
6 · The paper itself

Abstract

backgroundIt remains unclear whether there is a difference in overall survival (OS) benefit between (m)FOLFIRINOX and gemcitabine-nab-paclitaxel as preoperative regimens for localised pancreatic adenocarcinoma. This study aimed to investigate the outcome of patients with resected localised pancreatic adenocarcinoma following (m)FOLFIRINOX versus gemcitabine-nab-paclitaxel.

methodsInternational multicentre retrospective study (16 centres, 8 countries, 3 continents), including consecutive patients after pancreatic resection for localised pancreatic adenocarcinoma following 2-6 months preoperative (m)FOLFIRINOX or gemcitabine-nab-paclitaxel (2010-2018). Primary endpoint was OS from start of preoperative chemotherapy. Cox regression analysis was performed to investigate the association of the preoperative chemotherapy regimen with OS, adjusted for confounders at diagnosis.

resultsOverall, 935 patients were included after resection of localised pancreatic adenocarcinoma following preoperative (m)FOLFIRINOX (65%) or gemcitabine-nab-paclitaxel (35%). Preoperative chemotherapy regimen (m)FOLFIRINOX was not associated with OS (HR = 0.83 [95% CI 0.64-1.08]), compared to gemcitabine-nab-paclitaxel. Interaction analysis showed stronger effect of (m)FOLFIRINOX in patients with a lower (i.e., non-elevated/marginally elevated) serum CA19-9 at diagnosis (p

conclusionThis international study found no OS benefit of preoperative (m)FOLFIRINOX in patients with resected localised pancreatic adenocarcinoma compared to gemcitabine-nab-paclitaxel.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidinePancreatic NeoplasmsAdultAgedAlbuminsFemaleFluorouracilGemcitabineHumansIrinotecanLeucovorinMaleMiddle AgedNeoadjuvant Therapy130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineFluorouracilfolfirinoxGemcitabineIrinotecanLeucovorinOxaliplatinPaclitaxel

Identifiers

PMID40328917
PMCPMC12238338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.